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Thus, dipyridamole may have therapeutic efficacy to preventDipyridamole inhibits PDGF-stimulated human peritoneal
or alleviate PF.mesothelial cell proliferation.
Background. It has been proposed that proliferation of hu-
man peritoneal mesothelial cells (HPMCs) accompanied by
collagen synthesis may contribute to the development of perito- The successful use of peritoneal dialysis (PD) as aneal fibrosis (PF) in patients of long-term continuous ambula-
long-term replacement therapy depends on the sustainedtory peritoneal dialysis (CAPD). However, the precise molecu-
integrity of the peritoneal membrane. Peritoneal fibrosislar mechanism regulating HPMC proliferation has never been
reported. Dipyridamole has been reported to have potential (PF), a serious complication found occasionally in patients
as an antiproliferative and antifibrotic agent. We investigated the on long-term PD, has been demonstrated to compromise
mechanism and effect of dipyridamole in regulation of HPMC the peritoneal membrane to a severe degree [1, 2]. Re-proliferation.
search examining the mechanisms underlying PF hasMethods. HPMCs were cultured from human omentum by
shown that proliferation of human peritoneal mesothelialan enzyme digestion method. Cell proliferation was measured
by the methyltetrazolium assay and intracellular cAMP was mea- cells (HPMCs) accompanied by collagen synthesis play
sured using an enzyme immunoassay kit. Cell-cycle distribution a certain role in the pathogenesis of PF [1, 2]. However,
of HPMC was analyzed by flow cytometry. Extracellular signal- the precise cellular mechanism regulating HPMC prolif-regulated protein kinase (p44/p42 ERK) activity and expressions
eration has, to our knowledge, never been reported.of cell-cycle proteins (cyclin D1, CDK4, pRB and p27Kip1) were
Platelet-derived growth factor (PDGF) has been re-determined by Western blotting.
Results. The addition of DP suppressed PDGF-stimulated ported to be elevated during peritoneal injury [3]. In rat
HPMC proliferation by cell-cycle arrest at the G1 phase. The pleural mesothelial cell culture, PDGF has been shown
antimitogenic effect of dipyridamole was mediated through the to stimulate PMC proliferation and collagen synthesis [4].
cAMP pathway. PDGF (25 ng/mL) increased the ERK1/2 activity
The extracellular signal-regulated protein kinase (ERK),of HPMC within 15 minutes, which maximized at 30 minutes,
namely, the ERK1/2 (p44/p42) cascade, is considered toand the pretreatment with dipyridamole (17g/mL) substantially
reduced the ERK response to PDGF by approximately 78.5%. play a critical role in the downstream signals of PDGF
PDGF induced elevated protein levels of cyclin D1, but the [5]. In both human [6–8] and rat [9] aortic smooth muscle
CDK4 protein level did not change. Dipyridamole and DBcAMP cells (SMC), PDGF stimulates the sustained activation
had no effect on the levels of cyclin D1 and CDK4 in PDGF- of ERK consistent with a role in cellular proliferation asstimulated HPMC. PDGF decreased p27Kip1 and induced pRB
well as initiating DNA synthesis. Furthermore, it has beenphosphorylation of HPMC. In contrast, dipyridamole prevented
shown that abrogation of ERK expression activation us-PDGF-induced p27Kip1 degradation and attenuated PDGF-
stimulated pRB phosphorylation. ing antisense approaches abolishes PDGF-stimulated
Conclusion. Dipyridamole appears to inhibit PDGF-stimu- DNA synthesis in SMC [10] as well as in fibroblasts [11].
lated HPMC proliferation through attenuated ERK activity, Thus, in PF where accelerated HPMC proliferation is apreservation of p27Kip1, and decreased pRB phosphorylation.
feature, strategies designed to inhibit the PDGF-stimu-
lated ERK activation of HPMC may be clinically rele-
vant to the prevention or retardation of PF.Key words: extracellular protein kinase cascade, dipyridamole, fibrosis,
cell signaling, p27Kip1, signal transduction. Dipyridamole [2,6-bis(diethanolamino)-4,8-dipiperi-
dinopyrimido-(5,4-d)-yrimidine] is used as an antiplate-Received for publication June 20, 2000
let agent [12]. In addition to its antiplatelet activity, it hasand in revised form March 22, 2001
Accepted for publication March 26, 2001 been shown to exert antiproliferative effects on human
vascular SMC [8], human mesangial cells [13], and rat 2001 by the International Society of Nephrology
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mesangial cells [14]. Dipyridamole has been well docu- ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT),
dibutyryl-cAMP (DBcAMP), 3-isobutyl-1-methylxan-mented to act as a phosphodiesterase inhibitor that in-
creases intracellular cAMP [12, 13]. In rat aortic SMC thine (IBMX), human recombinant PDGF-AB, and other
tissue culture reagents were purchased from Sigma (St.[9] and mesangial cells [15] it has been shown that raising
intracellular cAMP results in the inhibition of agonist- Louis, MO, USA). The enzyme immunoassay (EIA) kits
for cAMP were obtained from Cayman Chemical (Annstimulated ERK. Our previous report demonstrated that
dipyridamole, through increased intracellular cAMP, Arbor, MI, USA). Selective cAMP-dependent protein
kinase (PKA) inhibitor, H-89, was obtained from Calbio-may inhibit rat mesangial cell proliferation and reduce
the expression of collagen 1(I) mRNA [14]. However, chem (La Jolla, CA, USA). Bicinchoinic acid (BCA)
reagents were obtained from Pierce (Rockford, IL, USA).its mechanism remains undetermined.
Cell proliferation is governed by the cell-cycle machin- Anti-phospho-ERK1/2 and anti-ERK1/2 were purchased
from New England Biolabs (Beverly, MA, USA). Anti-ery. In mammalian cells, progression through the cell
cycle is dependent on the balance of positive and nega- CDK4, anti-cyclin D1, anti-pRB, and anti-p27Kip1 antibod-
ies were obtained from Santa Cruz Biotechnology (Santative regulatory cell-cycle proteins [16]. Cyclin D1 plays a
vital role in G1 phase progression. Cyclin D1, when bound Cruz, CA, USA). Dipyridamole was generously provided
by Boehringer Ingelheim. All other chemicals used wereto its catalytic partner, the cyclin-dependent kinase 4
(CDK4), may result in the formation of active cyclin D1/ of analytical grade.
CDK4 complex, which is responsible for the phosphory-
Establishment of human PMC culturelation of the retinoblastoma gene product (pRB). Un-
phosphorylated pRB negatively controls G1 progression, Specimens of human omentum were obtained from
abdominal surgical procedures for elective gastric cancerand the phosphorylated form of pRB is essential and
required for proliferation of normal cells [17, 18]. Cyclin- resection and the omentum was grossly inspected as nor-
mal. The HPMC culture was performed as previouslykinase inhibitors (CKIs) negatively regulate the cell cycle
by inhibiting the cyclin D1/CDK4 complex. p27Kip1 is re- reported [21, 22]. Briefly, the surgically removed human
omentum was washed three times with PBS and thengarded as a major CKI of the G1 phase and is most
directly involved in cell cycle restriction control [19, 20]. digested with trypsin ethylenediaminetetraacetic acid
(EDTA; 0.125%; GIBCO) for 15 minutes. After centrif-In quiescent Balb/c-3T3 cells, the p27 Kip1 level is high
and the cell cycle stops in G1 phase [19]. A reduction of ugation, the cell pellet was washed with culture medium
and then seeded into a gelatin-coated (1 mg/mL) flask.p27Kip1 expression by PDGF results in cell-cycle re-entry
and proliferation of rat mesangial cells [20]. While cyclins Medium was changed on the third day. RPMI-1640 me-
dium containing 20% FCS, penicillin (100 U/mL), strep-and CDKs have been well investigated in a wide range
of mammalian cell types, there has been, to our knowl- tomycin (100 g/mL), and insulin (30 g /mL) was used.
After two to four days, the cells became confluent andedge, no report detailing their induction and regulation
in HPMCs. were subcultured with medium containing 10% FCS.
HPMCs were identified by the presence of vimentin andOur current study found that dipyridamole arrested
HPMC at the G1 phase. Furthermore, we identified the cytokeratin, but without desmin and factor VIII-related
antigen, by the immunoflurescence method. All experi-ERK cascade and determined the expression of cell-
cycle regulatory proteins in HPMCs. Our data show that ments were performed in passage 1–3 cells.
dipyridamole inhibited PDGF-stimulated HPMC prolif-
Cell proliferation assayeration mainly through attenuated ERK activity and al-
terations of cell-cycle proteins. A modified MTT assay was used to evaluate HPMC
proliferation as previously reported [14, 21, 22]. The
amount of MTT uptake (absorbance at 570 nm) by
METHODS
HPMC was found to vary linearly with cell numbers
Materials ranging from 4000 cells/well to 12.8  104 cells/well were
loaded in 96-well plates. Therefore, 5000 cells/well forFetal calf serum (FCS) was obtained from Biochrome
KG (Berlin, Germany). Culture flasks and plates were each MTT assay. Cells growing in log phase were trypsin-
ized and plated down in 96-well plates with RPMI-1640purchased from Corning (Corning, NY, USA) and pre-
coated with 1.6 g/cm2 of Vitrogen 100 (Celtrix Lab, medium containing 10% FCS. Various concentrations
of treatment agents were added after overnight plating.Palo Alto, CA, USA) before cell loading. Trypsin-EDTA,
RPMI-1640 medium, glutamine, and trypan blue were The medium and drug were changed every three days.
After additional incubations of 24 to 120 hours, 20 Lobtained from GIBCO (Grand Island, NY, USA). Aproti-
nin, adenosine 5-triphosphate (ATP), leupeptin, phenyl- MTT solutions (5 mg/mL in PBS) were added to the
culture medium. Cells were further incubated at 37Cmethylsulfonyl fluoride (PMSF), sodium orthovanadate
(Na3VO4), bovine serum albumin (BSA), 3-[4,5-dimeth- for four hours, and then the medium was replaced by
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100L ethanol. Absorbance at the reference wavelength Measurement of ERK activities
of 630 nm and test wavelength of 570 nm was measured The Western blotting analysis of ERK phosphorylation
by an ELISA reader. All experiments were repeated five was performed by using phospho-specific antibodies (New
times. The inhibition of HPMC growth was calculated England Biolabs, Beverly, MA, USA) according to the
as follows [21, 22]: percentage of inhibition  1  [ab- manufacturer’s protocol. Briefly, HPMCs were 0.5% FCS
sorbance of (test well  initial plating)/absorbance of starved for 48 hours and then stimulated with PDGF (25
(control  initial plating)]  100%. ng/mL) at different time points. For evaluating the inhibi-
tory effect of dipyridamole on PDGF-stimulated ERKIntracellular cAMP assay
activation, we incubated HPMC with 17 g/mL dipyri-
Three  105 HPMCs/well were loaded into a six-well damole for 30 minutes before stimulation with 25 ng/mL
plate with RPMI-1640 medium containing 10% FCS. PDGF for another 30 minutes and then used Western
After cells became subconfluent, they were washed twice blotting. In addition, lanes of cells were treated with H89
with warm RPMI-1640 medium and then mixed with (3 to 10 mol/L) for 30 minutes before dipyridamole. Cell
various concentrations of agents. After five minutes of lysates (50 g protein) were separated by SDS-PAGE
incubation, the supernatants were discarded and ice-cold (12%) and then transferred to PVDF membrane (Milli-
95% methanol was added to each well. After 30 minutes pore, Bedford, MA, USA). For immunodetection, the
of incubation at 4C, the supernatants evaporated and membranes were probed with phospho-specific ERK anti-
cAMP was measured using EIA kits. The cells in wells body (1:1000) followed by incubation with peroxidase-
were lysed by 0.1 mol/L NaOH, and protein content was conjugated secondary antibodies (1:4000). Bands were
measured by a bicinchoninic acid assay, using BSA as visualized with ECL system (Amersham).
the standard [23].
Western blot analysis of cell-cycle proteins
Flow cytometric analysis of cell cycle
For Western blot analysis, 50 g total protein extract
Six  105 HPMCs were seeded into 10 cm diameter were denatured by boiling for five minutes at 100C and
dishes and growth-arrested by 0.5% FCS for 48 hours. then separated on a 12% SDS-PAGE gel. For detection
Flow cytometry analysis of cell-cycle distribution of of pRB, a 7.5% SDS-PAGE gel was used. After electro-
HPMCs was performed 24 hours after treatment with
phoresis, the gels were electroblotted onto PVDF mem-
the indicated conditions. Briefly, cells were washed twice
brane (Millipore), and then stained with Coomassie blue
with PBS, harvested by trypsinization, centrifuged, and
to check for a complete protein transfer. The Ponceaus-Sresuspended with 1 mL cold PBS, and then fixed in
staining was applied to ensure that protein loading wasmethanol for 30 minutes on ice. After two washes with
equal. Blots were incubated in 1  PBS containing 0.1%PBS, approximately 106 fixed cells were incubated in 1
Tween-20 and 5% non-fat dry milk powder to block non-mg/mL RNase (Calbiochem, San Diego, CA, USA) at
specific antibody binding. This was followed by a two-37C for 30 minutes, followed by staining of the DNA
hour incubation at room temperature with antibodies ofwith 1 g/L propidium iodide (Sigma) at 4C for 30
either cyclin D1, CDK4, pRB, or p27Kip1. Controls in-minutes in the dark; 105 cells of each sample were ana-
cluded omitting the primary antibody or replacing thelyzed with a Coulter EPICS 753 flow cytometer, and the
primary antibody with rabbit serum. Western blots werepercentages of cells within the G1, S, and G2/M phases
developed by the ECL system.of the cell cycle were determined [24].
Statistical analysisCell preparations and protein extraction
The results are expressed as mean  SEM, unlessHuman peritoneal mesothelial cells were grown in 10 cm
otherwise stated. These statistical analyses were carrieddishes until subconfluent, growth-arrested for 48 hours
out using StatView IV on a personal computer. Statisticalwith medium containing 0.5% FCS and then treated. After
significance (P 	 0.05) was evaluated using the Studenttreatment, HPMCs were harvested at indicated time
t test or one way analysis of variance with a modifiedpoints with 200 L ice-cold lysis buffer (50 mmol/L Tris-
t test performed using the Bonferroni correction.HCl, pH 7.5, 150 mmol/L NaCl, 10% glycerol, 1% Triton
X-100, 2 mmol/L EDTA, 2 mmol/L EGTA, 40 mmol/L

-glycerophosphate, 50 mmol/L NaF, 10 mmol/L sodium RESULTS
pyrophosphate, 200 mol/L sodium orthovanadate, 10 g
Dipyridamole inhibits PDGF-stimulatedleupeptin/mL, 200 units of aprotinin/mL, 1 mol/L pep-
proliferation of HPMCsstatin A, 1 mmol/L PMSF, 100 nmol/L okadaic acid). The
Growth curve experiments of HPMCs in response tocell lysate was centrifuged at 14,000 rpm for 10 minutes,
PDGF with or without dipyridamole were performed toand the protein concentration of the supernatant was mea-
sured by a BCA protein assay (Pierce, Rockford, IL, USA). evaluate the effect of dipyridamole on PDGF-stimulated
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HPMC proliferation (Fig. 1). As expected, the addition
of PDGF at a dosage of 25 ng/mL resulted in a significant
increase of HPMC proliferation compared with that of
unstimulated cells. This effect was clearly reduced by pre-
treating the cells with dipyridamole before the addition
of PDGF. In time-response experiments, varying concen-
trations of dipyridamole were added 30 minutes before
the addition of PDGF (25 ng/mL) for 24 to 120 hours.
At concentrations above 6g/mL, dipyridamole resulted
in a dose-dependent inhibition of HPMC (Fig. 1A). The
dose-response effects of dipyridamole on HPMC prolif-
eration is shown in Figure 1B. Cells were incubated for
120 hours after adding varying concentrations of dipyri-
damole and a fixed dose (25 ng/mL) of PDGF. When
compared with the effect of PDGF alone, significant inhi-
bition of HPMC proliferation was observed at 6 g/mL
dipyridamole. Dipyridamole, at concentrations of 6 g/mL
and 17 g/mL, inhibited PDGF-stimulated HPMC pro-
liferation by 40.1 and 57.0%, respectively. Therefore, a
higher concentration of dipyridamole (17 g/mL) was
in the following experiments to show its effects on ERK
cascade and cell-cycle progressions of HPMC.
To exclude the potentially toxic effect of such a con-
centration of dipyridamole on proliferative HPMC, cell
viability tests were performed by the trypan blue exclu-
sion method and by measuring the lactate dehydroge-
nase (LDH) activity of the supernatant as we previously
described [21, 22]. No differences in numbers of dead
cells in supernatant and adherent HPMC fractions were
found between the control and dipyridamole-treated
wells. The levels of LDH did not increase after one- to
five-day incubation periods in the dipyridamole-treated
wells, which excluded the cell membrane damage on
HPMC by dipyridamole (data not shown).
Dipyridamole-induced cell-cycle arrest of HPMC
at the G1 phase
To investigate the cellular mechanism of this inhibi-
tory effect of dipyridamole on HPMC growth, cell-cycle
distribution was determined by flow cytometry (Fig. 2).
When HPMCs were starved for 48 hours on low serum
(0.5% FCS), 79.6  4.1% of the cells were arrested in
the G1 phase of the cell cycle. When the cells were treated
with PDGF (25 ng/mL) for 24 hours, 14.3  5.2% and
26.1  6.3% of the HPMCs were distributed in the S
and G2/M phases, respectively. In contrast, 81.5 4.5%
of the HPMCs were still in the G1 phase 24 hours afterFig. 1. Dipyridamole inhibits platelet-derived growth factor (PDGF 25
ng/mL)-stimulated human peritoneal mesothelial cell (HPMC) growth. (A) incubation with PDGF (25 ng/mL) in the presence of
Time-response curve: Varying concentrations of dipyridamole were added
dipyridamole (17 g/mL). Because dipyridamole hasafter overnight plating of HPMC and further incubated for one to five
days. Symbols are: () control; () PDGF; () PDGF  dipyridamole been shown to exert its action by increasing intracellular
2g/mL; () PDGFdipyridamole 6g/mL; () PDGFdipyridamole
cAMP [12–14], we also evaluated the effect of IBMX17 g/mL. (B) Dose-response study: HPMCs were incubated for 120
hours after addition of varying concentrations of dipyridamole and a on cell-cycle distributions of HPMCs. A similar cell-cycle
fixed dosage (25 ng/mL) of PDGF. *P	 0.05, **P	 0.01, compared with distribution was observed in cells treated with PDGFPDGF. Each point represents the mean  SEM of three experiments
performed in triplicate. (25 ng/mL) plus IBMX (1 mmol/L).
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Fig. 2. Flow cytometry analysis for cell-cycle distribution. Subconfluent HPMCs were growth arrested by 0.5% FCS for 48 hours (A) and then changed
into mediums in the presence of PDGF (25 ng/mL) alone (B) or (C) PDGF plus 17 g/mL dipyridamole or (D) PDGF plus IBMX (1 mmol/L). The
x axis shows DNA content; the y axis shows the number of cells. The experiments were repeated four times with similar results observed.
Dipyridamole increases intracellular cAMP lular cAMP levels were elevated in a dose-dependent
levels in HPMCs manner by dipyridamole. The addition of dipyridamole
at concentrations of 6 and 17 g/mL resulted in a signifi-Dipyridamole is known to function as a phosphodies-
cant increase of intracellular cAMP levels in HPMCs.terase inhibitor to increase intracellular cAMP levels
The addition of IBMX, as expected, increased the intra-[12, 13]. Thus, the effect of dipyridamole on levels of
cellular cAMP level in HPMCs.intracellular cAMP was studied. We measured cAMP
levels after incubating HPMC with varying concentrations
PKA inhibitor reversed the effect of dipyridamoleof dipyridamole (2, 6, and 17 g/mL). In these experi-
To elucidate if the growth inhibitory actions of dipyri-ments, IBMX (1 mmol/L), a known phosphodiesterase
inhibitor, was used as a positive control (Fig. 3). Intracel- damole was through the increased cAMP, the growth
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Fig. 3. Effect of dipyridamole on intracellular cAMP levels as mea-
sured by a cAMP kit. Intracellular cAMP levels were elevated in a Fig. 4. Effect of dipyridamole (D, 17 g/mL) and DBcAMP (C, 0.5
dose-dependent manner by dipyridamole. IBMX (1 mmol/L), a known mmol/L) on PDGF-stimulated HPMC proliferation. MTT assay was
phosphodiesterase inhibitor, was used as a positive control. *P 	 0.01, performed on the fifth day. H-89 (H, 3 mol/L) nearly completely
**P 	 0.05, relative to control. All experiments were performed four reversed the inhibitory effect of dipyridamole or DBcAMP on PDGF-
times. stimulated HPMC proliferation. In the absence of dipyridamole, H-89
did not independently result in HPMC proliferation. *P 	 0.01 vs.
PDGF alone. Data represent the mean  SEM of four experiments.
inhibitory effect of DBcAMP, a membrane-permeable
analogue of the cyclic nucleotide, was investigated next in
dipyridamole or DBcAMP. In the absence of dipyridam-cultured HPMC. The addition of DBcAMP (0.5 mmol/L)
ole, H-89 did not independently activate ERK1/2 inresulted in an inhibitory effect on PDGF-stimulated
HPMCs. Taken together, these results indicated that theHPMC proliferation (Fig. 4). To confirm that the inhibi-
inhibitory effect of dipyridamole on PDGF-stimulatedtory effect of dipyridamole on HPMC proliferation was
HPMC proliferation, as well as downstream ERK activa-through the activated cAMP-dependent kinase (PKA)
tion, is dependent of the activation of the PKA pathway.pathway, additional experiments were carried out using
the cell-permeable PKA inhibitor H-89. We found that
G1 cyclin/CDK expression of HPMCs in the presenceH-89 could overcome the growth inhibitory effects of
PDGF and dipyridamoledipyridamole and DBcAMP (Fig. 4). In the absence of
Because the ERK cascade is involved in gene expres-dipyridamole or DBcAMP, H-89 did not independently
sion of cyclin D1 and dipyridamole arrests HPMC in theresult in HPMC proliferation.
G1/S transition and is associated with an attenuated ERK
Dipyridamole inhibits PDGF-induced ERK activation activity, we questioned whether the inhibitory effect of
dipyridamole might be due to alterations of cyclin D1The ERK cascade is the central mitogenic signaling
and CDK4 following PDGF stimulation. First, kineticpathway downstream of PDGF stimulation. Therefore,
studies were performed to determine the protein expres-we studied the possible inhibitory effect of PDGF-stimu-
sion of cyclin D1. Low serum (0.5% FCS)-starved HPMCslated ERK activation by dipyridamole. Western blotting
were stimulated with 25 ng/mL PDGF and then wereof ERK1/2 phosphorylation was applied for the evaluation
harvested for Western blotting analysis at the time pointof ERK activities. Figure 5 shows that PDGF (25 ng/mL)
indicated. Western blot analysis indicated that there wasincreased ERK1/2 activity by 3.7-fold at 15 minutes above
a low level of protein expression for cyclin D1 (34 kD)baseline, and maximal activation (6.2-fold) of ERK1/2 was
in quiescent (0 hour) HPMCs (Fig. 6). During PDGFobserved at 30 minutes after addition of PDGF. There-
stimulation, protein levels of cyclin D1 rose between 0fore, we chose this time point for additional experiments.
to 4 hours and reached maximal levels around 8 to 12Pretreatment of HPMC with dipyridamole (17 g/mL)
hours after stimulation. Unlike cyclin D1, the CDK4 (32substantially reduced the ERK1/2 response to PDGF.
kD) protein level remained constant in quiescent andDipyridamole reduced PDGF-stimulated ERK1/2 activity
PDGF-stimulated cells (Fig. 6). We next investigated theby approximately 78.5%. Similar results were obtained
effects of dipyridamole and DBcAMP on protein levelsfollowing pretreatment with 0.5 mmol/L DBcAMP (data
of cyclin D1 and CDK4. In contrast to our expectations,not shown). Again, the PKA inhibitor H-89 (concentration
3 mol/L) completely reversed the inhibitory effect of dipyridamole (Fig. 6) and DBcAMP (data not shown)
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Fig. 6. Kinetics of expression of CDK4 (32 kD) and cyclin D1 (34 kD)
proteins upon stimulation with PDGF (25 ng/mL) and the effect of
dipyridamole (17g/mL) upon their expression. Lysates (50 g protein/
lane) of HPMCs were analyzed by using specific antibodies to CDK4
and cyclin D1. Quiescent HPMCs (0 h) were incubated with PDGF (25Fig. 5. Evaluation of inhibitory dipyridamole (DP, 17 g/mL) on ng/mL) alone or in the presence of dipyridamole (17 g/mL) and then
PDGF (25 ng/mL)-stimulated ERK1/2 activation in HPMC. Cell lysates were harvested at indicated time points for Western blotting analysis.
were immunoblotted with anti-phospho-ERK1/2 for ERK activation. The blot is representative of four such studies. Densitometric analysis
H-89 (unit: mol/L) was added to overcome the inhibitory effect of of four separate experiments with similar results are shown at the
dipyridamole on PDGF-stimulated ERK activation. Another aliquot bottom. #P  NS vs. PDGF-treated HPMC at respective time points.
of cell lysate mixtures was immunoblotted with anti-ERK1/2 antibody
for protein levels, which were not significantly affected during treatment.
Shown at the top is a representative blot from one experiment out of
five with similar results. The mean results of densitometric analysis of
four separate experiments are shown at the bottom. Values in the graph
are expressed as fold increase over control. *P 	 0.01, DP-treated vs.
PDGF-treated at 30 minutes (lane 3). #P  NS vs. PDGF alone at 30
minutes (lane 3).
Fig. 7. Immunoblot for pRB. After PDGF treatment, hyperphosphory-had no effect on cyclin D1 levels in PDGF-stimulated
lation of pRB slows electrophoretic mobility of the protein, creatingHPMC lysates. Similarly, the addition of either dipyri- the appearance of a double or widened band (gel shift). Immunoblots
damole (Fig. 6) or DBcAMP (data not shown) had no in lysates of HPMCs showed hyperphosphorylated form of pRB as
early as 8 hours after PDGF (25 ng/mL) stimulation and was observedeffect on CDK4 protein levels.
for 24 hours. In contrast, pRB hyperphosphorylation did not occur in
HPMC incubated with PDGF and dipyridamole (DP, 17 g/mL). ThisDipyridamole attenuates PDGF-stimulated pRB experiment result was typical of 5 experiments. (control, 0.5% FCS-
phosphorylation in HPMCs starved HPMCs).
Western blot analysis utilizing a polyclonal antibody
against pRB was performed to evaluate pRB phosphory-
lation, which is the downstream from cyclin D1/CDK4 pRB was almost completely blocked. Thus, the addition
complex and is necessary for G1 phase restriction. In of dipyridamole resulted in an attenuated pRB phos-
PDGF-stimulated HPMC, the hyperphosphorylated form phorylation.
of pRB, which was detected as a slower migrating band
Dipyridamole prevents PDGF-stimulated degradationin immunoblot analysis, was readily detected within 8
of p27Kip1 in HPMCshours and was observed at 24 hours (Fig. 7). In contrast,
in HPMCs incubated with PDGF in the presence of In other mammalian cells, protein levels of p27Kip1 in-
crease in serum-deprived cells and decrease when cellsdipyridamole, the hyperphosphorylated active form of
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Fig. 8. Growth-arrested HPMCs were stimulated with 25 ng/mL PDGF
in the presence or absence of 17 g/mL dipyridamole (DP). At the time
indicated, cellular extracts (50g protein/lane) were electrophoresed on
15% SDS-PAGE and immunoblotted with a polyclonal p27Kip1 antibody.
The data are representative of four such studies with similar results.
Fig. 9. Induction of p27 and hypophosphorylation of pRB by dipyri-
damole is PKA dependent. In experiments of H-89, HPMCs were pre-
treated with H-89 (10 mol/L) for 30 minutes and then were treated with
are stimulated by mitogen to enter the cell cycle [18]. In PDGF (25 ng/mL) in the presence or absence of dipyridamole (17 g/mL)
for another 16 hours. In PDGF-treated HPMCs, hyperphosphorylationour experiments using cultured HPMCs, protein levels
of pRB and decrease in protein level of p27Kip1 were observed. H-89,of p27Kip1 decreased in a time-dependent manner after when added before dipyridamole, reverted PDGF-stimulated pRB hyper-
treatment with PDGF (Fig. 8). Eight hours after PDGF phosphorylation. The maintenance effect of p27Kip1 by dipyridamole was
also attenuated in the presence of H-89. Shown is a representative blotstimulation, p27Kip1 protein levels decreased approxi-
from one experiment out of four with similar results.
mately 45% and continued to decrease, reaching a mini-
mal level at 12 to 24 hours (nearly 15 to 20% of unstimu-
lated cells). In contrast, dipyridamole prevented the
reduction of p27Kip1 expression by PDGF. By 24 hours, 400 mg per day) is about 1 to 3 g/mL [25]. In our culture
cells treated with PDGF and dipyridamole preserved system, an inhibitory effect of dipyridamole was demon-
nearly 80% of the p27Kip1 expressed in unstimulated cells. strated starting at a concentration of 6 g/mL (Fig. 1).
With regard to the other CKIs (p16INK4a, p15INK4b, and However, the serum level may not represent exactly the
p21waf1/cip1), no significant differences of their expressions tissue level of dipyridamole. Dipyridamole can be admin-
were found in dipyridamole- and/or PDGF-treated istered through an intraperitoneal route in patients on
HPMCs (data not shown). peritoneal dialysis, and, therefore, a higher intraperito-
neal concentration of dipydiamole may be achieved. This
Stabilization of p27Kip1 and hypophosphorylation of implies that dipyridamole has therapeutic value for the
pRB by dipyridamole is PKA-dependent prevention or alleviation of PF in vivo as well as in daily
practice.Since dipyridamole elevates intracellular cAMP levels,
One of the cellular mechanisms of dipyridamole iswe assumed that the regulatory effect of dipyridamole
through attenuation of the ERK cascade of HPMC. Toon p27Kip1 and pRB could be through the PKA pathway.
our knowledge, this is the first study to elucidate the roleTo examine the validity of this hypothesis, H-89 was
and activation of the ERK cascade in HPMCs. Himmel-used to assess the role of PKA in p27Kip1 induction and
farb and Couper demonstrated that dipyridamole, byin pRB hypophosphorylation by dipyridamole in PDGF-
antagonizing the ERK1/2, inhibited PDGF-induced vas-treated HPMCs. As shown in Figure 9, PDGF induced
cular SMC proliferation [8]. In accordance with thosea dramatic decrease in p27Kip1 levels. In H-89 pre-treated
findings, in HPMC we observed a reduced ERK1/2 re-HPMC, dipyridamole was unable to prevent p27Kip1 elim-
sponse to PDGF by dipyridamole (Fig. 5). Dipyridamoleination by PDGF. Further, PDGF was able to induce
has been well documented to exert its pharmacologicalpRB hyperphosphorylation in HPMC when H-89 was
effects via increasing intracellular cAMP [12–14]. A fewadded before dipyridamole. Taken together, these re-
studies have reported that cAMP inhibits PDGF-inducedsults suggest that the cell-cycle regulatory effect of dipyr-
mitogenesis through attenuating ERK activity [26, 27].idamole in HPMC is PKA-dependent.
To examine whether the suppressive effect of dipyridam-
ole on ERK1/2 activity in HPMC was also through in-
DISCUSSION creased cAMP, we examined the effects of raising intra-
Normal turnover of the mesothelium is essential to cellular cAMP on ERK1/2 activity in HPMCs. Figure 5
maintain peritoneal membrane integrity. However, the shows that dipyridamole (17 g/mL) suppressed PDGF-
overproliferation of HPMCs and subsequent accumula- stimulated ERK1/2 activation in HPMC. Moreover, we
tion of extracellular matrix may contribute to the devel- further demonstrated that the inhibitory effect of dipyri-
opment of PF. Our study demonstrates an inhibitory damole could be reversed in the presence of H-89. Taken
effect of dipyridamole on PDGF-stimulated HPMC pro- together, these results indicate that the cAMP-PKA
liferation. The usual plasma level of dipyridamole after pathway most likely mediates the suppression of PDGF-
stimulated ERK1/2 activation by dipyridamole.an oral administration of a conventional dosage (150 to
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Another mechanism for the inhibitory effect of dipyri- by preventing the depletion of p27Kip1 and modulating
pRB phosphorylation. Dipyridamole may have therapeu-damole is through alterations of the cell-cycle progression
in HPMC. Using flow cytometry (Fig. 2), we demon- tic value for future clinical application in PF prevention.
strated, for the first time to our knowledge, that dipyri-
damole inhibits HPMC at the G1 phase. In other cell ACKNOWLEDGMENTS
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(Fig. 6). Similar effects on cyclin D1 and CDK4 were ob-
APPENDIXserved after addition of DBcAMP (data not shown). Kato
et al demonstrated in a macrophage cell line that cAMP Abbreviations used in this article are: cAMP, cyclic adenosine 35-
monophosphate; CAPD, continuous ambulatory peritoneal dialysis;had no effect on cyclin D1 levels [30]. The previously
CDK, cyclin-dependent kinase; CKI, cyclin kinase inhibitors; DBcAMP,mentioned findings highlight the fact that while antipro- dibutyryl-cAMP; DP, dipyridamole; EIA, enzyme immunoassay; ERK,
liferative agents target cell cycle machinery, the exact extracellular signal-regulated protein kinase; FCS, fetal calf serum;
HPMC, human peritoneal mesothelial cells; IBMX, 3-isobutyl-l-methyl-mechanisms differ depending on the agent and the cell
xanthine; LDH, lactate dehydrogenase; MTT, 3-[4,5-dimethylthiazol-types. As dipyridamole has no effect on the cyclin D1 and 2-yl]-2,5-diphenyltetrazolium bromide; PBS, phosphate-buffered saline;
CDK4 of HPMC (Fig. 6), the blockade of pRB phosphory- PD, peritoneal dialysis; PDGF, platelet-derived growth factor; PF,
peritoneal fibrosis; PKA, protein kinase A; PMSF, phenylmethylsulfo-lation observed in dipyridamole-treated HPMC (Fig. 7)
nyl fluoride; pRB, retinoblastoma gene product; PVDF, polyvinylidenemay be based on other mechanisms.
difluoride; SMC, smooth muscle cells.
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